PLUS THERAPEUTICS Revenue and Competitors

Austin, TX USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • PLUS THERAPEUTICS's estimated annual revenue is currently $2.2M per year.(i)
  • PLUS THERAPEUTICS's estimated revenue per employee is $100,500

Employee Data

  • PLUS THERAPEUTICS has 22 Employees.(i)
  • PLUS THERAPEUTICS grew their employee count by -12% last year.

PLUS THERAPEUTICS's People

NameTitleEmail/Phone
1
President & CEOReveal Email/Phone
2
VP & Chief Financial OfficerReveal Email/Phone
3
VP, Clinical ResearchReveal Email/Phone
4
VP, Corporate Strategy and New Product PlanningReveal Email/Phone
5
VP, Clinical AffairsReveal Email/Phone
6
Assistant Director Quality AssuranceReveal Email/Phone
7
Director, Chemistry,Manufacturing, and ControlsReveal Email/Phone
8
Director, Capital Markets, Investor Relations, Commercial Growth StrategyReveal Email/Phone
9
Director Market AccessReveal Email/Phone
10
Manager, Drug Development and ProductionReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$32.4M16120%N/AN/A
#2
$16.3M817%N/AN/A
#3
$18.7M9316%N/AN/A
#4
$62.5M0N/AN/AN/A
#5
$12.3M617%N/AN/A
#6
$3.2MN/A$22.2MN/A
#7
$184.1M91638%$50MN/A
#8
$27.7M1388%N/AN/A
#9
$112.4M5598%N/AN/A
#10
$12.5M6211%N/AN/A
Add Company

What Is PLUS THERAPEUTICS?

PLUS THERAPEUTICS (Nasdaq: PSTV) is a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for adults and children with rare and difficult-to-treat cancers. Our lead drug candidate, Rhenium-186 Nanoliposome, is being evaluated in the NIH-supported multi-center ReSPECT clinical trials for patients with recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer.

keywords:N/A

N/A

Total Funding

22

Number of Employees

$2.2M

Revenue (est)

-12%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.4M22-19%N/A
#2
$2.2M22N/AN/A
#3
$2.2M22N/AN/A
#4
$2.2M22N/AN/A
#5
$3.2M22N/AN/A